CNBX — CNBX Pharmaceuticals Inc.
—
OTC ·
Health Care ·
Pharmaceuticals ·
CIK 1343009 ·
Last close
$0.00
Market Cap
$160.6K
52W High
$0.00
52W Low
$0.00
ADV30
3,665,089
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| May 2026 | 0 | 0 | -162,763 | -154,165 | 12,795 | 9,487 | 2,672,509 |
| Feb 2026 | 0 | 0 | -72,963 | -44,098 | 14,899 | 12,154 | 2,548,447 |
| Nov 2025 | 0 | — | -64,002 | -113,719 | 11,162 | 7,703 | 2,584,133 |
| Aug 2025 | 0 | — | -129,731 | -150,109 | 18,437 | 15,111 | 2,514,730 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-154,169
Investing CF
$0
Financing CF
$150,008
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.00
As of
2026-09-27
Balance + Analyst (yfinance extras)
Retained Earnings
$-25,580,358
Inventory
—
Receivables
$3,308
ST Investments
—
EBIT TTM
$-431,555
Pretax Income TTM
$-462,091
Interest Exp TTM
—
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Aug 2025 | 0 | -271,691 | -313,976 | 18,437 | 2,514,730 | -2,496,293 | -171,305 |
| Aug 2024 | 130,074 | -583,140 | -695,198 | 31,383 | 2,511,363 | -2,479,980 | -244,269 |
| Aug 2023 | 410,165 | -931,380 | -3,710,234 | 499,039 | 2,516,328 | -2,017,289 | -112,521 |
| Aug 2022 | 29,958 | -2,953,970 | -4,392,381 | 811,166 | 2,443,477 | -1,632,311 | -1,679,192 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| PRPH | ProPhase Labs, Inc. | $155.9K | $0.01 | — |
| RGBP | Regen BioPharma Inc | $167.5K | $0.00 | — |
| PTPI | Petros Pharmaceuticals, Inc. | $169.5K | $0.00 | — |
| OCEA | Ocean Biomedical, Inc. | $185.9K | $0.00 | — |
| AVCRF | Avricore Health Inc. | $101.1K | $0.00 | — |
Recent Insider Activity
No insider activity indexed for this ticker.